After-Hours Stock Movers
Socket Mobile (NASDAQ: SCKT) 80% HIGHER; reported Q2 EPS of $0.27, $0.24 better than the analyst estimate of $0.03. Revenue for the quarter came in at $6 million versus the consensus estimate of $4.07 million.
Boston Beer Co. (NYSE: SAM) 18.3% LOWER; reported Q2 EPS of $4.75, $2.10 worse than the analyst estimate of $6.85. Revenue for the quarter came in at $602.8 million versus the consensus estimate of $665.25 million.
Snap (NYSE: SNAP) 16% HIGHER; reported Q2 EPS of $0.10, $0.11 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $982.1 million versus the consensus estimate of $844.98 million. Average monetizable daily active users (mDAU) were 206 million for Q2, compared to 186 million in the same period of the previous year and compared to 199 million in the previous quarter. Snap sees Q3 2021 revenue of $1.07-1.09 billion, versus the consensus of $1.01 billion.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) 15.3% LOWER; entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 5,454,546 shares of common stock of the Company, at a price to the public of $0.55 per share, less underwriting discounts and commissions.
Clearfield, Inc. (NASDAQ: CLFD) 10.3% HIGHER; reported Q3 EPS of $0.44, $0.14 better than the analyst estimate of $0.30. Revenue for the quarter came in at $38.7 million versus the consensus estimate of $32.1 million. Clearfield, Inc. sees FY2021 revenue of $130-135 million, versus the consensus of $122.9 million.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) 6% HIGHER; reported preliminary net product revenue for the quarter ended June 30, 2021, and in-market unit sales for June 2021. The Company is reporting preliminary second quarter 2021 total net product revenue of approximately $11.7 million, representing a greater than 600% year-over-year increase versus the second quarter 2020 and an approximately 60% sequential increase over the first quarter of 2021. Net product revenue of DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg for the quarter ended June 30, 2021 is estimated to be $11.1 million, and net product revenue of ReSure® Sealant for the quarter ended June 30, 2021 is estimated to be $0.6 million. (*** consensus is $11.6 million)
Skechers USA (NYSE: SKX) 8.5% HIGHER; reported Q2 EPS of $0.88, $0.39 better than the analyst estimate of $0.49. Revenue for the quarter came in at $1.66 billion versus the consensus estimate of $1.48 billion. Skechers USA sees Q3 2021 EPS of $2.55-$2.65, versus the consensus of $2.10. Skechers USA sees Q3 2021 revenue of $6.15-6.25 billion, versus the consensus of $5.91 billion.